The company’s shift to the U.S. market involves rapid scaling of logistics and distribution infrastructure. This transition coincides with a strengthened clinical profile, marked by new cost-effectiveness data from Italy and expanded hospital reimbursement pathways in Germany. As of June 30, 2026, the firm held 41.7 million euros in cash and equivalents, providing a runway for its commercial launch activities.
Implantica Targets US Market Growth After RefluxStop FDA Approval
With FDA approval for its RefluxStop device now secured, Vaduz-based Implantica is pivoting toward a major American expansion. The company reported a 66% surge in second-quarter net sales to 717,000 euros, bolstered by a 60% increase in European sales and the publication of a significant 602-patient safety study.
European operations continue to provide a stable foundation, with the network of Centers of Excellence growing to over 60 locations. Recent additions include the MD Anderson Madrid facility and new sites across Switzerland and the UK. Financially, the company managed to narrow its operating loss to 4.2 million euros for the quarter, down from 4.5 million euros in the same period last year, while maintaining a high adjusted gross margin of 94%.
Comments (0)
No comments yet. Be the first!